CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26104907 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Carla Vargas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Medicina Interna, Facultad de Medicina Oriente, Universidad de Chile, Santiago 8330014, Chile. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoplastic Stem Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo, FONDECYT de Iniciación.
Abstract (Originalsprache)
Therapy resistance remains a major barrier to improving outcomes in HER2-positive breast cancer, with dormant tumor cells (DTCs) and cancer stem cells (CSCs) playing critical roles in recurrence and treatment failure. Herein, we investigated the interplay between dormancy and CSCs features in HER2-amplified breast cancer cell models and evaluated the role of the JAK1–STAT3 axis in sustaining these therapy-resistant phenotypes. Using an in vitro dormancy model induced by HER2 inhibition, we observed a reversible quiescent state characterized by decreased proliferation and viability, accompanied by a significant increase in the CSC marker CD44. CD44 expression was rapidly induced following HER2 inhibition, preceding measurable effects on cell viability, and persisted throughout the dormancy phase. CD44-positive populations showed reduced sensitivity to HER2 inhibition and displayed robust proliferative recovery upon therapy withdrawal. Functional studies revealed that the inhibition of JAK1, but not STAT3, impaired the recovery of CD44-positive populations and decreased their proliferative capacity, suggesting a critical role for JAK1 in maintaining the CSC phenotype during therapy. These findings underscore the importance of CD44 as a marker and mediator of therapy resistance and suggest that targeting CD44-positive cells or the JAK1 signaling axis could improve the efficacy of HER2-targeted therapies. Our study provides novel insights into the mechanisms underlying dormancy and CSC induction in HER2-positive breast cancer and highlights potential strategies to mitigate therapy resistance and prevent disease recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Medicina Interna, Facultad de Medicina Oriente, Universidad de Chile, Santiago 8330014, Chile.
- Instituto Oncológico, Fundación Arturo López Pérez, Santiago 7500710, Chile.
- Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA.
- Escuela de Tecnología Médica, Facultad de Ciencias de la Salud, Universidad San Sebastián, Santiago 7510157, Chile.
ORCID-Profile: Rodrigo L Castillo
Förderung
- Agencia Nacional de Investigación y Desarrollo
- FONDECYT de Iniciación
Zitieren
APA
Vargas, C., Aguirre-Ducler, A., Cereceda, K., Quijada, S., Escobar-Gómez, N., Castillo, R. L., & Escobar-Aguirre, M. (2025). CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104907
Vancouver
Vargas C, Aguirre-Ducler A, Cereceda K, Quijada S, Escobar-Gómez N, Castillo RL, et al. CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104907
BibTeX
@article{Vargas2025,
author = {Vargas, Carla and Aguirre-Ducler, Adam and Cereceda, Karina and Quijada, Sebastián and Escobar-Gómez, Nicolás and Castillo, Rodrigo L and Escobar-Aguirre, Matías},
title = {CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26104907}
}
EUVIMED